Celsion’s GEN-1 Immunotherapy Could Help Women with Advanced Ovarian Cancer, Trial Shows

Celsion’s GEN-1 Immunotherapy Could Help Women with Advanced Ovarian Cancer, Trial Shows
Celsion has released the latest update from the its OVATION Phase 1b clinical trial (NCT02480374), showing that combining GEN-1 with standard of care for newly diagnosed advanced ovarian cancer patients induces superior progression-free survival (PFS) rates compared to historical controls. The study is enrolling women with newly diagnosed stage III and IV ovarian cancer to receive Celsion’s innovative immunotherapy, GEN-1 – an

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *